Introduction
============

Hepatoid adenocarcinoma (HAC) is a very rare finding, and generally occurs in the stomach, ovaries, and lungs. The term hepatoid adenocarcinoma was first introduced by Ishikura *et al*. in 1985 \[[@B1]\]. This report presents only the ninth case of HAC in the urinary bladder to be published in the literature, and reviews the previously reported cases.

Case presentation
=================

A 49-year-old Japanese woman was diagnosed as having a breast tumor, and a total mastectomy was subsequently performed. A histology study of the breast tumor revealed a ductal carcinoma *in situ* with the pathological stage TisN0M0. A year after surgery, abdominal computed tomography (CT) revealed a mass lesion in the urinary bladder (Figure [1](#F1){ref-type="fig"}). There were no abnormal findings in the liver. Serological markers for hepatitis B and C viruses were also within normal limits. Cystoscopy revealed a solitary tumor on the left wall of the bladder (Figure [2](#F2){ref-type="fig"}). The tumor appeared to occur from the subepithelial tissue. Based on the findings, our patient was diagnosed as having a bladder tumor, therefore trans-urethral resection of the bladder tumor (TURBT) was performed. The tumor cells were microscopically typed as a hepatocellular carcinoma, featuring large, polygonal cells with marked nuclear atypia and eosinophilic granular or clear cytoplasma (Figure [3](#F3){ref-type="fig"}). Immunohistochemical staining test results were positive for α-fetoprotein (AFP) (Figure [4](#F4){ref-type="fig"}). A histology study of the tumor revealed a typical HAC, predominantly resembling a hepatocellular carcinoma. The tumor had spread to the subepithelial connective tissue below the non-atypical transitional epithelium, and the pathological stage was T1N0M0. After surgery, her serum AFP concentration was within normal limits. Chemotherapy was not administered. At 20 months after surgery, our patient has had no evidence of recurrence.

![Abdominal computed tomography showing a 6mm mass in the bladder.](1752-1947-7-12-1){#F1}

![Cystoscopy showing a solitary tumor on the left wall of the bladder.](1752-1947-7-12-2){#F2}

![**Histopathological features of hepatoid adenocarcinoma of the urinary bladder.** The tumor was composed of large, polygonal cells with eosinophilic cytoplasm. The cells were predominantly arranged in a trabecular pattern (hematoxylin and eosin stained specimen, ×100).](1752-1947-7-12-3){#F3}

![**Immunohistochemical profile of hepatoid adenocarcinoma of the urinary bladder.** Intra-cytoplasmic cells positive for α-fetoprotein, ×100.](1752-1947-7-12-4){#F4}

Discussion
==========

HAC is a rare tumor, which is characterized by the morphological phenotype of a hepatocellular carcinoma. HAC is defined by the reproduction of a pattern similar to that of a hepatocellular carcinoma, with a combination of histopathological findings of solid nests and trabecular structures of polygonal atypical cells with wide granular cytoplasm and an immunochemical expression of AFP. Before a diagnosis of HAC is made, the metastases of a hepatocellular carcinoma should be ruled out.

Metzgeroth *et al*. recently published an evaluation of 262 HAC cases \[[@B2]\]. The stomach was the most common location with a frequency of 63 percent, followed by the ovaries (10 percent), lungs (4 percent), gallbladder (3 percent), pancreas (4 percent), uterus (4 percent), and urinary bladder (3 percent). HAC usually presents in older patients. The male to female ratio was 2.4:1 and the median age at diagnosis was 65 years (range 21 to 88 years). HAC is treated like other adenocarcinomas of the common type, depending on the organ system involved. The prognosis of HAC is considered to be unfavorable. HAC is regarded to be an aggressive neoplasm associated with a high proportion of metastases at the time of diagnosis. The lymph nodes, the liver and the brain are common metastatic sites. The survival rate of 83 cases with various HAC indicated 43 patients had died within the first 12 months, and 40 patients were alive for more than 12 months. The one-year survival rate (expressed as a percentage) was about 55 percent and the median overall period of survival was 11 months (range 0 to 102 months) \[[@B2]\].

The first case of HAC in the urinary bladder was reported by Sinard *et al*. in 1994 \[[@B3]\] and only eight cases have been reported to date \[[@B3]-[@B7]\]. The main clinical and pathological data from the previously reported cases are presented in Table [1](#T1){ref-type="table"}\[[@B2]-[@B6]\]. As can be seen from the previous cases and our patient's case, the patients were six men and three women. Their mean age was 68 years (range: 49 to 89 years). Hematuria was the initial symptom in six patients. Six cases received serum AFP examinations and five yielded positive results. However, HAC was not always accompanied by high levels of serum AFP \[[@B8]\]. Three cases were treated with cystectomies and six with TURBT. The pathological stages were T1 (n=3), T2 (n=3), and T3 (n=3). The prognosis of HAC was considered to be unfavorable, like that of other organs. Three patients underwent cystectomies and died of the disease 12 to 19 months later due to lung metastases. However, three cases of pT1 appeared to have been cured by TURBT and, post-operatively, they have had no evidence of recurrence more than 20 months later. The prolonged patient survival might be related to the low pathological stage of the tumor. Further studies with a large number of cases are required to classify the risk and management of HAC in the urinary bladder.

###### 

Characteristics of patients with hepatoid adenocarcinoma (HAC) in the urinary bladder

  **Case no., reference**       **Age/sex**   **Symptoms**     **Tumor size**   **Serum AFP**   **Therapy**        **pT stage**   **Follow-up, months**   **Status**
  ----------------------------- ------------- ---------------- ---------------- --------------- ------------------ -------------- ----------------------- -----------------------
  1\. Sinard \[[@B3]\]          68/F          Hydronephrosis   2.5cm            N/A             TUR                T3a            17                      AWD
  2\. Yamada \[[@B4]\]          89/F          Hematuria        6.5×5.5cm        12,700ng/mL     Total cystectomy   T2b            1                       Lost to follow-up
  3\. Burgues \[[@B5]\]         71/M          Hematuria        NA               WNL             TUR                T2             N/A                     AWD
  4\. Lopez-Beltran \[[@B6]\]   66/M          Hematuria        6×5cm            1065ng/mL       Total cystectomy   T3a            14                      Lung metastatsis, DOD
  5\. Lopez-Beltran \[[@B6]\]   85/M          Hematuria        80g, resected    N/A             TUR                T2             12                      Lung metastatsis, DOD
  6\. Lopez-Beltran \[[@B6]\]   61/M          Hematuria        5×5cm            2025ng/mL       Total cystectomy   T3a            19                      Lung metastatsis, DOD
  7\. Lopez-Beltran \[[@B6]\]   68/M          Hematuria        1.5cm            1070ng/mL       TUR                T1             26                      NED
  8\. Kawamura \[[@B7]\]        79/M          Hematuria        1cm              39.08ng/mL      TUR                Ta             20                      NED
  9\. Present case              49/F          \-               6mm              NA              TUR                T1             20                      NED

AFP = α-fetoprotein; AWD = alive with disease; DOD = died of disease; NED = alive with no evidence of disease; NA = not available; TUR = trans-urethral resection; WNL = within normal limits.

Conclusions
===========

Hepatoid adenocarcinoma is a highly aggressive tumor mimicking the histological appearance of hepatocellular carcinoma. There are few reports describing hepatoid adenocarcinoma of the urinary bladder. It is important to be aware of atypical cancer localizations in order to reach a correct diagnosis.
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